Biosimulation Market

The report "Biosimulation Market by Phase (Drug Discovery, Preclinical, Regulatory), Modality (Antibody, Peptide), Application (Molecular Design, PK/PD, QSP, Trial Simulation, Disease Modeling), Indication (Cardio, Onco), End User (CRO, Pharma) – Global Forecast to 2031", is projected to grow from USD 4.27 billion in 2026 and to reach USD 9.24 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 16.7% during the forecast period.

Browse 300 market data Tables and 50 Figures spread through 400 Pages and in-depth TOC on "Biosimulation Market by Phase (Drug Discovery, Preclinical, Regulatory), Modality (Antibody, Peptide), Application (Molecular Design, PK/PD, QSP, Trial Simulation, Disease Modeling), Indication (Cardio, Onco), End User (CRO, Pharma) – Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/biosimulation-market-838.html

Drug development costs are increasing, as are the needs for both faster and more successful products to market. As a result of these increasing costs and needs, there has been a significant rise in the use of biosimulation technology by pharmaceutical and biotechnology companies. Biosimulation platforms allow drug developers to simulate the assessment of drug candidates in silico; determine optimal dosing strategies; evaluate the safety profiles of drug candidates; rank drug candidates for lead generation purposes; and conduct this virtual testing prior to expensive in vivo experimentation. The evolving use of computational methods in the fields of precision medicine, biologics, and cell & gene therapy will further drive demand for biosimulation that can accurately model complex biological systems and predict patient responses to treatment. Additionally, continuing advances in artificial intelligence (AI), machine learning, and high-performance computing will be enhancing the accuracy, scalability, and usability of biosimulation platforms, resulting in an even more rapid generation of insights by researchers, while supporting data-driven decisions throughout the lifecycle of drug development. Nonetheless, there exist numerous barriers to the continued growth of this market, which include: the development and validation of predictive models is complex; the high-quality biological and clinical data necessary for these types of analyses are in short supply; there is a significant shortage of specialized computational scientists; and the substantial investments that must be made for software deployment, model development, and ongoing maintenance.

“By offering, services segment to grow at faster rate than software segment during forecast period”

In terms of offering, the services segment is anticipated to witness a higher CAGR than the software segment in the biosimulation market, driven by various contributors, including increasing complexities in drug development, widespread adoption of MIDD approaches, and an increase in demand for specialized expertise in PBPK modeling, QSP, pharmacometrics, and regulatory modeling. A considerable number of pharmaceutical and biotech firms, particularly those that are small or mid-size enterprises, do not possess an in-house capability for biosimulation services; consequently, they rely on third-party service providers for the development, validation, regulatory support, data analysis, and strategic consulting of models. Additionally, the services sector will continue to benefit from the increasing integration of artificial intelligence, machine learning, and advanced analytics into the biosimulation workflow; this often requires scientific and/or technical expertise. As biologics, cell and gene therapies, and precision medicine continue to grow, there will be an increase in demand for outsourced biosimulation services, ultimately helping organizations reduce their R&D risks, improve decision-making, and accelerate timelines to develop products.

“By deployment mode, on-premises segment accounted for largest market share in 2025”

By deployment model, on-premises solutions accounted for the largest share of the biosimulation market in 2025. This dominance can be attributed to the need for stringent data security, intellectual property protection, and regulatory compliance in pharmaceutical and biotechnology research. Biosimulation workflows often involve highly sensitive preclinical, clinical, and proprietary molecular data, prompting many organizations to maintain simulation platforms within their internal IT environments. Large pharmaceutical companies, in particular, have made substantial investments in on-premise high-performance computing (HPC) infrastructure to support computationally intensive applications such as PBPK modeling, QSP, molecular dynamics, computational chemistry, and AI-driven drug discovery. Furthermore, on-premise deployments offer greater control over data governance, system customization, and integration with existing R&D systems, making them the preferred choice for organizations managing large-scale and complex drug development programs.

“Asia Pacific to be fastest-growing regional market during forecast period”

The biosimulation market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Asia Pacific is projected to be the fastest-growing regional market for biosimulation, driven by increasing investments in pharmaceutical and biotechnology innovation, expanding drug discovery capabilities, and rising adoption of computational approaches across the drug development lifecycle. Countries such as China, India, Japan, South Korea, and Singapore are strengthening their life sciences ecosystems through government-backed research initiatives, growing biopharmaceutical manufacturing capacity, and increasing integration of artificial intelligence and advanced analytics into R&D workflows. The region is also witnessing growing demand for cost-effective strategies to accelerate drug development and improve research productivity, encouraging the adoption of biosimulation technologies such as PBPK modeling, QSP, pharmacometrics, and molecular modeling. Furthermore, the expanding presence of global pharmaceutical companies, contract research organizations, and academic research institutes is contributing to greater utilization of biosimulation platforms across emerging markets in the region.

Key Market Players:

The key players in the biosimulation market include Certara (US), Dassault Systèmes (France), Schrödinger, Inc. (US), Simulations Plus (US), Advanced Chemistry Development, Inc. (Revvity) (Canada), and Chemical Computing Group ULC (Canada), among others.

Don’t miss out on business opportunities in Biosimulation Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com